Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA 02111, USA.
Arterioscler Thromb Vasc Biol. 2011 Aug;31(8):1871-80. doi: 10.1161/ATVBAHA.111.229070. Epub 2011 May 26.
Aldosterone (Aldo) antagonism prevents cardiovascular mortality by unclear mechanisms. Aldo binds to the mineralocorticoid receptor (MR), a ligand-activated transcription factor, which is expressed in human vascular cells. Here we define the early Aldo-regulated vascular transcriptome and investigate the mechanisms of gene regulation by Aldo in the vasculature that may contribute to vascular disease.
Gene expression profiling of Aldo-treated mouse aortas identified 72 genes regulated by Aldo. These genes are overrepresented in Gene Ontology categories involved in vascular function and disease. Quantitative reverse transcription-polymerase chain reaction was used to confirm and further explore mechanisms of vascular gene regulation by Aldo. Aldo-regulated vascular gene expression was inhibited by actinomycin D and MR antagonists supporting a transcriptional MR-dependent mechanism. Aldo regulation of a subset of genes was enhanced in the setting of vascular endothelial denudation and blocked by the free radical scavenger Tempol, supporting synergy between Aldo and vascular injury that is oxidative stress dependent. In the aortic arch, a region predisposed to atherosclerosis, the injury-enhanced genes also demonstrated enhanced expression compared with the descending aorta, both at baseline and after Aldo exposure. Furthermore, the clinically beneficial MR antagonist spironolactone inhibited expression of the identified genes in aortic tissue from humans with atherosclerosis.
This study defines the Aldo-regulated vascular transcriptome and characterizes a subset of proatherogenic genes with enhanced Aldo-stimulated, oxidative stress-dependent expression in the setting of vascular injury and in areas predisposed to atherosclerosis. Inhibition of MR regulation of these genes may play a role in the protective effects of Aldo antagonists in patients with vascular disease, and these pathways may provide novel drug targets to prevent atherosclerosis in humans.
醛固酮(Aldo)通过不明机制拮抗作用预防心血管死亡率。Aldo 与盐皮质激素受体(MR)结合,后者是一种配体激活的转录因子,在人类血管细胞中表达。在这里,我们定义了 Aldo 早期调节的血管转录组,并研究了 Aldo 在血管中调节基因的机制,这些机制可能导致血管疾病。
用 Aldo 处理的小鼠主动脉的基因表达谱分析确定了 72 个受 Aldo 调节的基因。这些基因在涉及血管功能和疾病的基因本体论类别中过表达。定量逆转录聚合酶链反应用于证实并进一步探索 Aldo 调节血管基因表达的机制。Aldo 调节的血管基因表达被放线菌素 D 和 MR 拮抗剂抑制,支持转录依赖于 MR 的机制。Aldo 对一组基因的调节在血管内皮剥脱的情况下增强,并且被自由基清除剂 Tempol 阻断,支持 Aldo 和血管损伤之间的协同作用,这是氧化应激依赖性的。在动脉弓,易患动脉粥样硬化的区域,与降主动脉相比,损伤增强的基因在基线和 Aldo 暴露后也表现出增强的表达。此外,临床上有益的 MR 拮抗剂螺内酯抑制了动脉粥样硬化患者主动脉组织中鉴定基因的表达。
本研究定义了 Aldo 调节的血管转录组,并描述了一组具有增强的 Aldo 刺激、氧化应激依赖性表达的前动脉粥样硬化基因,这些基因在血管损伤和易患动脉粥样硬化的区域中表达增强。MR 对这些基因的调节抑制可能在血管疾病患者 Aldo 拮抗剂的保护作用中发挥作用,这些途径可能为预防人类动脉粥样硬化提供新的药物靶点。